Role of a critical visceral adipose tissue threshold (CVATT) in metabolic syndrome: implications for controlling dietary carbohydrates: a review

Eric S Freedland, Eric S Freedland

Abstract

There are likely many scenarios and pathways that can lead to metabolic syndrome. This paper reviews mechanisms by which the accumulation of visceral adipose tissue (VAT) may contribute to the metabolic syndrome, and explores the paradigm of a critical VAT threshold (CVATT). Exceeding the CVATT may result in a number of metabolic disturbances such as insulin resistance to glucose uptake by cells. Metabolic profiles of patients with visceral obesity may substantially improve after only modest weight loss. This could reflect a significant reduction in the amount of VAT relative to peripheral or subcutaneous fat depots, thereby maintaining VAT below the CVATT. The CVATT may be unique for each individual. This may help explain the phenomena of apparently lean individuals with metabolic syndrome, the so-called metabolically normal weight (MONW), as well as the obese with normal metabolic profiles, i.e., metabolically normal obese (MNO), and those who are "fit and fat." The concept of CVATT may have implications for prevention and treatment of metabolic syndrome, which may include controlling dietary carbohydrates. The identification of the CVATT is admittedly difficult and its anatomical boundaries are not well-defined. Thus, the CVATT will continue to be a work in progress.

Figures

Figure 1
Figure 1
Critical Visceral Adipose Tissue Threshold (CVATT). According to the hypothesis, there is an individual range for accumulating a critical amount of visceral adipose tissue (VAT). Insulin sensitivity is important for weight gain and accumulation of VAT. Once the critical VAT threshold (CVATT) is reached, insulin resistance occurs, which may be protective initially and impair further weight and fat gain. Continuation of VAT accumulation can lead to metabolic syndrome. However, only a modest weight loss (5–10 percent) with accompanying VAT loss can reverse the process.
Figure 2
Figure 2
VAT versus SCAT
Figure 3
Figure 3
This diagram provides an overview of how behavioral and environmental factors can lead to VAT obesity and, ultimately, metabolic syndrome and related disorders.

References

    1. Bjorntorp P. Metabolic implications of body fat distribution. Diabetes Care. 1991;14:1132–1143.
    1. Lamarche B. Abdominal obesity and its metabolic complications: implications for the risk of ischaemic heart disease. Coron Artery Dis. 1998;9:473–481.
    1. Lafontan M, Berlan M. Do regional differences in adipocyte biology provide new pathophysiological insights? Trends Pharmacol Sci. 2003;24:276–283. doi: 10.1016/S0165-6147(03)00132-9.
    1. Montague CT, O'Rahilly S. The perils of portliness: causes and consequences of visceral adiposity. Diabetes. 2000;49:883–888.
    1. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev. 2000;21:697–738. doi: 10.1210/er.21.6.697.
    1. Ross R, Goodpaster B, Kelley D, Boada F. Magnetic resonance imaging in human body composition research. From quantitative to qualitative tissue measurement. Ann N Y Acad Sci. 2000;904:12–17.
    1. Ravussin E, Smith SR. Increased fat intake, impaired fat oxidation, and failure of fat cell proliferation result in ectopic fat storage, insulin resistance, and type 2 diabetes mellitus. Ann N Y Acad Sci. 2002;967:363–378.
    1. Kim SK, Kim HJ, Hur KY, Choi SH, Ahn CW, Lim SK, Kim KR, Lee HC, Huh KB, Cha BS. Visceral fat thickness measured by ultrasonography can estimate not only visceral obesity but also risks of cardiovascular and metabolic diseases. Am J Clin Nutr. 2004;79:593–599.
    1. Blair D, Habicht JP, Sims EA, Sylwester D, Abraham S. Evidence for an increased risk for hypertension with centrally located body fat and the effect of race and sex on this risk. Am J Epidemiol. 1984;119:526–540.
    1. Bergstrom RW, Newell-Morris LL, Leonetti DL, Shuman WP, Wahl PW, Fujimoto WY. Association of elevated fasting C-peptide level and increased intra-abdominal fat distribution with development of NIDDM in Japanese-American men. Diabetes. 1990;39:104–111.
    1. Carr Darcy B., Utzschneider Kristina M., Hull Rebecca L., Kodama Keiichi, Retzlaff Barbara M., Brunzell John D., Shofer Jane B., Fish Brian E., Knopp Robert H., Kahn Steven E. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III Criteria for the Metabolic Syndrome. Diabetes. 2004;53:2087–2094.
    1. Matsuzawa Y, Shimomura I, Nakamura T, Keno Y, Kotani K, Tokunaga K. Pathophysiology and pathogenesis of visceral fat obesity. Obes Res. 1995;3 Suppl 2:187S–194S.
    1. Cheal KL, Abbasi F, Lamendola C, McLaughlin T, Reaven GM, Ford ES. Relationship to insulin resistance of the adult treatment panel III diagnostic criteria for identification of the metabolic syndrome. Diabetes. 2004;53:1195–1200.
    1. Liao Y, Kwon S, Shaughnessy S, Wallace P, Hutto A, Jenkins AJ, Klein RL, Garvey WT. Critical evaluation of adult treatment panel III criteria in identifying insulin resistance with dyslipidemia. Diabetes Care. 2004;27:978–983.
    1. McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med. 2003;139:802–809.
    1. Reaven GM. Insulin resistance, cardiovascular disease, and the metabolic syndrome: how well do the emperor's clothes fit? Diabetes Care. 2004;27:1011–1012.
    1. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults - Findings from the Third National Health and Nutrition Examination Survey. JAMA-J Am Med Assoc. 2002;287:356–359. doi: 10.1001/jama.287.3.356.
    1. Meigs JB, Avruch J. The metabolic syndrome. Endocrinology Rounds (Massachusetts General Hospital) 2003;2:1–5.
    1. Einhorn D, Reaven GM, Cobin RH, Ford E, Ganda OP, Handelsman Y, Hellman R, Jellinger PS, Kendall D, Krauss RM, Neufeld ND, Petak SM, Rodbard HW, Seibel JA, Smith DA, Wilson PW. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract. 2003;9:237–252.
    1. Proceedings of the American College of Endocrinology Insulin Resistance Syndrome Conference. Washington, DC, USA. August 25-26, 2002. Endocr Pract. 2003;9 Suppl 2:22–112.
    1. Executive Summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III) Jama. 2001;285:2486–2497. doi: 10.1001/jama.285.19.2486.
    1. Balkau B, Charles MA, Drivsholm T, Borch-Johnsen K, Wareham N, Yudkin JS, Morris R, Zavaroni I, van Dam R, Feskins E, Gabriel R, Diet M, Nilsson P, Hedblad B. Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab. 2002;28:364–376.
    1. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15:539–553. doi: 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>;2-S.
    1. Katsuki A, Sumida Y, Urakawa H, Gabazza EC, Murashima S, Nakatani K, Yano Y, Adachi Y. Increased oxidative stress is associated with serum levels of triglyceride, insulin resistance, and hyperinsulinemia in Japanese metabolically obese, normal-weight men. Diabetes Care. 2004;27:631–632.
    1. Katsuki A, Sumida Y, Urakawa H, Gabazza EC, Murashima S, Maruyama N, Morioka K, Nakatani K, Yano Y, Adachi Y. Increased visceral fat and serum levels of triglyceride are associated with insulin resistance in Japanese metabolically obese, normal weight subjects with normal glucose tolerance. Diabetes Care. 2003;26:2341–2344.
    1. Ruderman N, Chisholm D, Pi-Sunyer X, Schneider S. The metabolically obese, normal-weight individual revisited. Diabetes. 1998;47:699–713.
    1. Sims EA. Are there persons who are obese, but metabolically healthy? Metabolism. 2001;50:1499–1504. doi: 10.1053/meta.2001.27213.
    1. Unger RH. Lipotoxic diseases. Annu Rev Med. 2002;53:319–336. doi: 10.1146/annurev.med.53.082901.104057.
    1. Unger RH. Lipid overload and overflow: metabolic trauma and the metabolic syndrome. Trends in Endocrinol & Metab. 2003;14:398–403. doi: 10.1016/j.tem.2003.09.008.
    1. Schaffer JE. Lipotoxicity: when tissues overeat. Curr Opin Lipidol. 2003;14:281–287. doi: 10.1097/00041433-200306000-00008.
    1. Boston Globe. Boston, MA; 1991.
    1. Arcaro G, Zamboni M, Rossi L, Turcato E, Covi G, Armellini F, Bosello O, Lechi A. Body fat distribution predicts the degree of endothelial dysfunction in uncomplicated obesity. Int J Obes Relat Metab Disord. 1999;23:936–942. doi: 10.1038/sj.ijo.0801022.
    1. Ziccardi P, Nappo F, Giugliano G, Esposito K, Marfella R, Cioffi M, D'Andrea F, Molinari AM, Giugliano D. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation. 2002;105:804–809. doi: 10.1161/hc0702.104279.
    1. Eckel RH. Obesity: disease or physiologic adaptation? In: Eckel R H, editor. Obesity: Mechanisms and Clinical Management. Philadelphia, Lippincott Williams & Wilkins; 2003.
    1. Landsberg L. The sympathetic nervous system, insulin resistance, and obesity. SNS Report (Servier) 2002;No.4:2–4.
    1. Unger RH. Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome. Endocrinology. 2003;144:5159–5165. doi: 10.1210/en.2003-0870.
    1. Westman EC, Mavropoulos J, Yancy WS, Volek JS. A review of low-carbohydrate ketogenic diets. Curr Atheroscler Rep. 2003;5:476–483.
    1. Eckel RH. Insulin resistance: an adaptation for weight maintenance. Lancet. 1992;340:1452–1453. doi: 10.1016/0140-6736(92)92633-Q.
    1. Swinburn BA, Nyomba BL, Saad MF, Zurlo F, Raz I, Knowler WC, Lillioja S, Bogardus C, Ravussin E. Insulin resistance associated with lower rates of weight gain in Pima Indians. J Clin Invest. 1991;88:168–173.
    1. Frayn KN, Humphreys SM, Coppack SW. Net carbon flux across subcutaneous adipose tissue after a standard meal in normal-weight and insulin-resistant obese subjects. Int J Obes Relat Metab Disord. 1996;20:795–800.
    1. Maffeis C, Moghetti P, Grezzani A, Clementi M, Gaudino R, Tato L. Insulin resistance and the persistence of obesity from childhood into adulthood. J Clin Endocrinol Metab. 2002;87:71–76. doi: 10.1210/jc.87.1.71.
    1. McGarry JD. Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes. 2002;51:7–18.
    1. Lewis GF, Carpentier A, Adeli K, Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev. 2002;23:201–229. doi: 10.1210/er.23.2.201.
    1. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403. doi: 10.1056/NEJMoa012512.
    1. Lindstrom J, Louheranta A, Mannelin M, Rastas M, Salminen V, Eriksson J, Uusitupa M, Tuomilehto J. The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care. 2003;26:3230–3236.
    1. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343–1350. doi: 10.1056/NEJM200105033441801.
    1. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, Hu ZX, Lin J, Xiao JZ, Cao HB, Liu PA, Jiang XG, Jiang YY, Wang JP, Zheng H, Zhang H, Bennett PH, Howard BV. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care. 1997;20:537–544.
    1. Goodpaster BH, Kelley DE, Wing RR, Meier A, Thaete FL. Effects of weight loss on regional fat distribution and insulin sensitivity in obesity. Diabetes. 1999;48:839–847.
    1. Esposito K, Nappo F, Giugliano F, Di Palo C, Ciotola M, Barbieri M, Paolisso G, Giugliano D. Meal modulation of circulating interleukin 18 and adiponectin concentrations in healthy subjects and in patients with type 2 diabetes mellitus. Am J Clin Nutr. 2003;78:1135–1140.
    1. Giugliano G, Nicoletti G, Grella E, Giugliano F, Esposito K, Scuderi N, D'Andrea F. Effect of liposuction on insulin resistance and vascular inflammatory markers in obese women. Br J Plast Surg. 2004;57:190–194. doi: 10.1016/j.bjps.2003.12.010.
    1. Cazes L, Deitel M, Levine RH. Effect of abdominal lipectomy on lipid profile, glucose handling and blood pressure in patients with truncal obesity. Obes Surg. 1996;6:159–166. doi: 10.1381/096089296765557123.
    1. Thorne A, Lonnqvist F, Apelman J, Hellers G, Arner P. A pilot study of long-term effects of a novel obesity treatment: omentectomy in connection with adjustable gastric banding. Int J Obes Relat Metab Disord. 2002;26:193–199. doi: 10.1038/sj.ijo.0801871.
    1. Klein S, Fontana L, Young VL, Coggan AR, Kilo C, Patterson BW, Mohammed BS. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N Engl J Med. 2004;350:2549–2557. doi: 10.1056/NEJMoa033179.
    1. Smith SR, Zachwieja JJ. Visceral adipose tissue: a critical review of intervention strategies. Int J Obes Relat Metab Disord. 1999;23:329–335. doi: 10.1038/sj.ijo.0800834.
    1. Busetto L. Visceral obesity and the metabolic syndrome: effects of weight loss. Nutr Metab Cardiovasc Dis. 2001;11:195–204.
    1. Hotamisligil GS. The irresistible biology of resistin. J Clin Invest. 2003;111:173–174. doi: 10.1172/JCI200317605.
    1. Alessi MC, Bastelica D, Morange P, Berthet B, Leduc I, Verdier M, Geel O, Juhan-Vague I. Plasminogen activator inhibitor 1, transforming growth factor-beta1, and BMI are closely associated in human adipose tissue during morbid obesity. Diabetes. 2000;49:1374–1380.
    1. Fain JN, Madan AK, Hiler ML, Cheema P, Bahouth SW. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology. 2004;145:2273–2282. doi: 10.1210/en.2003-1336.
    1. Pantanetti P, Garrapa GG, Mantero F, Boscaro M, Faloia E, Venarucci D. Adipose tissue as an endocrine organ? A review of recent data related to cardiovascular complications of endocrine dysfunctions. Clin Exp Hypertens. 2004;26:387–398. doi: 10.1081/CEH-120034142.
    1. Minocci A, Savia G, Lucantoni R, Berselli ME, Tagliaferri M, Calo G, Petroni ML, de Medici C, Viberti GC, Liuzzi A. Leptin plasma concentrations are dependent on body fat distribution in obese patients. Int J Obes Relat Metab Disord. 2000;24:1139–1144. doi: 10.1038/sj.ijo.0801385.
    1. Fain JN, Bahouth SW, Madan AK. TNFalpha release by the nonfat cells of human adipose tissue. Int J Obes Relat Metab Disord. 2004;28:616–622. doi: 10.1038/sj.ijo.0802594.
    1. Ouchi N, Kihara S, Arita Y, Nishida M, Matsuyama A, Okamoto Y, Ishigami M, Kuriyama H, Kishida K, Nishizawa H, Hotta K, Muraguchi M, Ohmoto Y, Yamashita S, Funahashi T, Matsuzawa Y. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation. 2001;103:1057–1063.
    1. Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, Yen FT, Bihain BE, Lodish HF. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci U S A. 2001;98:2005–2010. doi: 10.1073/pnas.041591798.
    1. Stefan N, Vozarova B, Funahashi T, Matsuzawa Y, Weyer C, Lindsay RS, Youngren JF, Havel PJ, Pratley RE, Bogardus C, Tataranni PA. Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes. 2002;51:1884–1888.
    1. Stefan N, Stumvoll M, Vozarova B, Weyer C, Funahashi T, Matsuzawa Y, Bogardus C, Tataranni PA. Plasma adiponectin and endogenous glucose production in humans. Diabetes Care. 2003;26:3315–3319.
    1. Chandran M, Phillips SA, Ciaraldi T, Henry RR. Adiponectin: more than just another fat cell hormone? Diabetes Care. 2003;26:2442–2450.
    1. Fisher FM, McTernan PG, Valsamakis G, Chetty R, Harte AL, Anwar AJ, Starcynski J, Crocker J, Barnett AH, McTernan CL, Kumar S. Differences in adiponectin protein expression: effect of fat depots and type 2 diabetic status. Horm Metab Res. 2002;34:650–654. doi: 10.1055/s-2002-38246.
    1. Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, Hotta K, Nishida M, Takahashi M, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation. 2000;102:1296–1301.
    1. Rajala MW, Scherer PE. Minireview: The adipocyte--at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology. 2003;144:3765–3773. doi: 10.1210/en.2003-0580.
    1. Hauner H, Wabitsch M, Pfeiffer EF. Differentiation of adipocyte precursor cells from obese and nonobese adult women and from different adipose tissue sites. Horm Metab Res Suppl. 1988;19:35–39.
    1. Adams M, Montague CT, Prins JB, Holder JC, Smith SA, Sanders L, Digby JE, Sewter CP, Lazar MA, Chatterjee VK, O'Rahilly S. Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation. J Clin Invest. 1997;100:3149–3153.
    1. Danforth E., Jr. Failure of adipocyte differentiation causes type II diabetes mellitus? Nat Genet. 2000;26:13. doi: 10.1038/79111.
    1. Frayn KN. Adipose tissue as a buffer for daily lipid flux. Diabetologia. 2002;45:1201–1210. doi: 10.1007/s00125-002-0873-y.
    1. Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, Cusi K, Mandarino LJ, DeFronzo RA. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab. 2002;87:2784–2791. doi: 10.1210/jc.87.6.2784.
    1. Nakamura T, Funahashi T, Yamashita S, Nishida M, Nishida Y, Takahashi M, Hotta K, Kuriyama H, Kihara S, Ohuchi N, Nishimura T, Kishino BI, Ishikawa K, Kawamoto T, Tokunaga K, Nakagawa C, Mineo I, Watanabe F, Tarui S, Matsuzawa Y. Thiazolidinedione derivative improves fat distribution and multiple risk factors in subjects with visceral fat accumulation--double-blind placebo-controlled trial. Diabetes Res Clin Pract. 2001;54:181–190. doi: 10.1016/S0168-8227(01)00319-9.
    1. Kelly IE, Han TS, Walsh K, Lean ME. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care. 1999;22:288–293.
    1. de Souza CJ, Eckhardt M, Gagen K, Dong M, Chen W, Laurent D, Burkey BF. Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance. Diabetes. 2001;50:1863–1871.
    1. Xu Haiyan, Barnes Glenn T., Yang Qing, Tan Guo, Yang Daseng, Chou Chieh J., Sole Jason, Nichols Andrew, Ross Jeffrey S., Tartaglia Louis A., Chen Hong. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003;112:1821–1830. doi: 10.1172/JCI200319451.
    1. Charriere G, Cousin B, Arnaud E, Andre M, Bacou F, Penicaud L, Casteilla L. Preadipocyte conversion to macrophage. Evidence of plasticity. J Biol Chem. 2003;278:9850–9855. doi: 10.1074/jbc.M210811200.
    1. Lehrke M, Lazar MA. Inflamed about obesity. Nat Med. 2004;10:126–127. doi: 10.1038/nm0204-126.
    1. Wagenknecht LE, Langefeld CD, Scherzinger AL, Norris JM, Haffner SM, Saad MF, Bergman RN. Insulin sensitivity, insulin secretion, and abdominal fat: the Insulin Resistance Atherosclerosis Study (IRAS) Family Study. Diabetes. 2003;52:2490–2496.
    1. Zierath JR, Livingston JN, Thorne A, Bolinder J, Reynisdottir S, Lonnqvist F, Arner P. Regional difference in insulin inhibition of non-esterified fatty acid release from human adipocytes: relation to insulin receptor phosphorylation and intracellular signalling through the insulin receptor substrate-1 pathway. Diabetologia. 1998;41:1343–1354. doi: 10.1007/s001250051075.
    1. Bjorntorp P. "Portal" adipose tissue as a generator of risk factors for cardiovascular disease and diabetes. Arteriosclerosis. 1990;10:493–496.
    1. Arner P. Regional adipocity in man. J Endocrinol. 1997;155:191–192.
    1. Stephens TW, Basinski M, Bristow PK, Bue-Valleskey JM, Burgett SG, Craft L, Hale J, Hoffmann J, Hsiung HM, Kriauciunas A, et al. The role of neuropeptide Y in the antiobesity action of the obese gene product. Nature. 1995;377:530–532. doi: 10.1038/377530a0.
    1. Kishida K, Kuriyama H, Funahashi T, Shimomura I, Kihara S, Ouchi N, Nishida M, Nishizawa H, Matsuda M, Takahashi M, Hotta K, Nakamura T, Yamashita S, Tochino Y, Matsuzawa Y. Aquaporin adipose, a putative glycerol channel in adipocytes. J Biol Chem. 2000;275:20896–20902. doi: 10.1074/jbc.M001119200.
    1. Lundgren M, Buren J, Ruge T, Myrnas T, Eriksson JW. Glucocorticoids Down-Regulate Glucose Uptake Capacity and Insulin-Signaling Proteins in Omental But Not Subcutaneous Human Adipocytes. J Clin Endocrinol Metab. 2004;89:2989–2997. doi: 10.1210/jc.2003-031157.
    1. Bjorntorp P. Endocrine abnormalities in obesity. Diabetes Reviews. 1997;5
    1. Marin P, Arver S. Androgens and abdominal obesity. Baillieres Clin Endocrinol Metab. 1998;12:441–451.
    1. Shadid S, Jensen MD. Ch 7: Endocrine control of fuel partitioning. In: Eckel R H, editor. Obesity: Mechanisms and Clinical Management. Philadelphia, Lippincott Williams & Williams; 2003.
    1. Matsuzawa Y. Pathophysiology and molecular mechanisms of visceral fat syndrome: the Japanese experience. Diabetes Metab Rev. 1997;13:3–13. doi: 10.1002/(SICI)1099-0895(199703)13:1<3::AID-DMR178>;2-N.
    1. Jensen MD. Androgen effect on body composition and fat metabolism. Mayo Clin Proc. 2000;75 Suppl:S65–8; discussion S68-9.
    1. Nestler JE. Obesity, insulin, sex steroids and ovulation. Int J Obes Relat Metab Disord. 2000;24 Suppl 2:S71–3.
    1. Lima N, Cavaliere H, Knobel M, Halpern A, Medeiros-Neto G. Decreased androgen levels in massively obese men may be associated with impaired function of the gonadostat. Int J Obes Relat Metab Disord. 2000;24:1433–1437. doi: 10.1038/sj.ijo.0801406.
    1. Kraemer WJ, Volek JS, Clark KL, Gordon SE, Puhl SM, Koziris LP, McBride JM, Triplett-McBride NT, Putukian M, Newton RU, Hakkinen K, Bush JA, Sebastianelli WJ. Influence of exercise training on physiological and performance changes with weight loss in men. Med Sci Sports Exerc. 1999;31:1320–1329. doi: 10.1097/00005768-199909000-00014.
    1. Turcato E, Zamboni M, De Pergola G, Armellini F, Zivelonghi A, Bergamo-Andreis IA, Giorgino R, Bosello O. Interrelationships between weight loss, body fat distribution and sex hormones in pre- and postmenopausal obese women. J Intern Med. 1997;241:363–372. doi: 10.1046/j.1365-2796.1997.120129000.x.
    1. Wabitsch M, Hauner H, Heinze E, Muche R, Bockmann A, Parthon W, Mayer H, Teller W. Body-fat distribution and changes in the atherogenic risk-factor profile in obese adolescent girls during weight reduction. Am J Clin Nutr. 1994;60:54–60.
    1. Marin P, Holmang S, Jonsson L, Sjostrom L, Kvist H, Holm G, Lindstedt G, Bjorntorp P. The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int J Obes Relat Metab Disord. 1992;16:991–997.
    1. Rebuffe-Scrive M, Marin P, Bjorntorp P. Effect of testosterone on abdominal adipose tissue in men. Int J Obes. 1991;15:791–795.
    1. Marin P, Krotkiewski M, Bjorntorp P. Androgen treatment of middle-aged, obese men: effects on metabolism, muscle and adipose tissues. Eur J Med. 1992;1:329–336.
    1. Bujalska IJ, Walker EA, Tomlinson JW, Hewison M, Stewart PM. 11Beta-hydroxysteroid dehydrogenase type 1 in differentiating omental human preadipocytes: from de-activation to generation of cortisol. Endocr Res. 2002;28:449–461. doi: 10.1081/ERC-120016822.
    1. Bujalska IJ, Kumar S, Stewart PM. Does central obesity reflect "Cushing's disease of the omentum"? Lancet. 1997;349:1210–1213. doi: 10.1016/S0140-6736(96)11222-8.
    1. Walker BR. 11beta-hydroxysteroid dehydrogenase type 1 in obesity. Obes Res. 2004;12:1–3.
    1. Engeli S, Bohnke J, Feldpausch M, Gorzelniak K, Heintze U, Janke J, Luft FC, Sharma AM. Regulation of 11beta-HSD genes in human adipose tissue: influence of central obesity and weight loss. Obes Res. 2004;12:9–17.
    1. Zurlo F, Larsen K, Bogardus C, Ravussin E. Skeletal muscle metabolism is a major determinant of resting energy expenditure. J Clin Invest. 1990;86:1423–1427.
    1. Ranneries C, Bulow J, Buemann B, Christensen NJ, Madsen J, Astrup A. Fat metabolism in formerly obese women. Am J Physiol. 1998;274:E155–61.
    1. Kelley DE, Goodpaster B, Wing RR, Simoneau JA. Skeletal muscle fatty acid metabolism in association with insulin resistance, obesity, and weight loss. Am J Physiol. 1999;277:E1130–41.
    1. Sinha R, Dufour S, Petersen KF, LeBon V, Enoksson S, Ma YZ, Savoye M, Rothman DL, Shulman GI, Caprio S. Assessment of skeletal muscle triglyceride content by (1)H nuclear magnetic resonance spectroscopy in lean and obese adolescents: relationships to insulin sensitivity, total body fat, and central adiposity. Diabetes. 2002;51:1022–1027.
    1. Kelley DE, Williams KV, Price JC, McKolanis TM, Goodpaster BH, Thaete FL. Plasma fatty acids, adiposity, and variance of skeletal muscle insulin resistance in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2001;86:5412–5419. doi: 10.1210/jc.86.11.5412.
    1. Colberg SR, Simoneau JA, Thaete FL, Kelley DE. Skeletal muscle utilization of free fatty acids in women with visceral obesity. J Clin Invest. 1995;95:1846–1853.
    1. Kelley DE, Goodpaster BH, Storlien L. Muscle triglyceride and insulin resistance. Annu Rev Nutr. 2002;22:325–346. doi: 10.1146/annurev.nutr.22.010402.102912.
    1. Mauriege P, Brochu M, Prud'homme D, Tremblay A, Nadeau A, Lemieux S, Despres JP. Is visceral adiposity a significant correlate of subcutaneous adipose cell lipolysis in men? J Clin Endocrinol Metab. 1999;84:736–742. doi: 10.1210/jc.84.2.736.
    1. Johnson JA, Fried SK, Pi-Sunyer FX, Albu JB. Impaired insulin action in subcutaneous adipocytes from women with visceral obesity. Am J Physiol Endocrinol Metab. 2001;280:E40–9.
    1. Cnop M, Landchild MJ, Vidal J, Havel PJ, Knowles NG, Carr DR, Wang F, Hull RL, Boyko EJ, Retzlaff BM, Walden CE, Knopp RH, Kahn SE. The concurrent accumulation of intra-abdominal and subcutaneous fat explains the association between insulin resistance and plasma leptin concentrations : distinct metabolic effects of two fat compartments. Diabetes. 2002;51:1005–1015.
    1. Giusti V, Suter M, Verdumo C, Gaillard RC, Burckhardt P, Pralong FP. Molecular determinants of human adipose tissue: differences between visceral and subcutaneous compartments in obese women. J Clin Endocrinol Metab. 2004;89:1379–1384. doi: 10.1210/jc.2003-031507.
    1. Snijder Marieke B, Dekker Jacqueline M, Visser Marjolein, Bouter Lex M, Stehouwer Coen DA, Kostense Piet J, Yudkin John S, Heine Robert J, Nijpels Giel, Seidell Jacob C. Associations of hip and thigh circumferences independent of waist circumference with the incidence of type 2 diabetes: the Hoorn Study. Am J Clin Nutr. 2003;77:1192–1197.
    1. Frayn KN. Visceral fat and insulin resistance--causative or correlative? Br J Nutr. 2000;83 Suppl 1:S71–7.
    1. Gabriely I, Ma XH, Yang XM, Atzmon G, Rajala MW, Berg AH, Scherer P, Rossetti L, Barzilai N. Removal of visceral fat prevents insulin resistance and glucose intolerance of aging: an adipokine-mediated process? Diabetes. 2002;51:2951–2958.
    1. Tiikkainen M, Bergholm R, Vehkavaara S, Rissanen A, Hakkinen AM, Tamminen M, Teramo K, Yki-Jarvinen H. Effects of identical weight loss on body composition and features of insulin resistance in obese women with high and low liver fat content. Diabetes. 2003;52:701–707.
    1. Tanko LB, Bagger YZ, Alexandersen P, Larsen PJ, Christiansen C. Central and peripheral fat mass have contrasting effect on the progression of aortic calcification in postmenopausal women. Eur Heart J. 2003;24:1531–1537. doi: 10.1016/S0195-668X(03)00319-1.
    1. Tanko Laszlo B., Bagger Yu Z., Alexandersen Peter, Larsen Philip J., Christiansen Claus. Peripheral adiposity exhibits an independent dominant antiatherogenic effect in elderly women. Circulation. 2003;107:1626–1631. doi: 10.1161/01.CIR.0000057974.74060.68.
    1. Snijder Marieke B., Dekker Jacqueline M., Visser Marjolein, Bouter Lex M., Stehouwer Coen D.A., Yudkin John S., Heine Robert J., Nijpels Giel, Seidell Jacob C. Trunk Fat and Leg Fat Have Independent and Opposite Associations With Fasting and Postload Glucose Levels: The Hoorn Study . Diabetes Care. 2004;27:372–377.
    1. Van Pelt RE, Evans EM, Schechtman KB, Ehsani AA, Kohrt WM. Contributions of total and regional fat mass to risk for cardiovascular disease in older women. Am J Physiol Endocrinol Metab. 2002;282:E1023–8.
    1. Lissner Lauren, Bjorkelund Cecilia, Heitmann Berit L., Seidell Jaap C., Bengtsson Calle. Larger hip circumference independently predicts health and longevity in a Swedish female cohort. Obes Res. 2001;9:644–646.
    1. Tanko LB, Bruun JM, Alexandersen P, Bagger YZ, Richelsen B, Christiansen C, Larsen PJ. Novel associations between bioavailable estradiol and adipokines in elderly women with different phenotypes of obesity: implications for atherogenesis. Circulation. 2004;In Press
    1. Tanko LB. Book. Book (Editor ed^eds) 2004
    1. Kahn Steven E., Prigeon Ronald L., Schwartz Robert S., Fujimoto Wilfred Y., Knopp Robert H., Brunzell John D., Porte Daniel, Jr. Obesity, body fat distribution, insulin sensitivity and Islet {{beta}}-cell function as explanations for metabolic diversity. J Nutr. 2001;131:354S–360.
    1. Abate N, Garg A, Peshock RM, Stray-Gundersen J, Grundy SM. Relationships of generalized and regional adiposity to insulin sensitivity in men. J Clin Invest. 1995;96:88–98.
    1. Goodpaster BH, Thaete FL, Simoneau JA, Kelley DE. Subcutaneous abdominal fat and thigh muscle composition predict insulin sensitivity independently of visceral fat. Diabetes. 1997;46:1579–1585.
    1. Haap M, Siewecke C, Thamer C, Machann J, Schick F, Haring HU, Szeimies RM, Stumvoll M. Multiple symmetric lipomatosis: a paradigm of metabolically innocent obesity? Diabetes Care. 2004;27:794–795.
    1. Krotkiewski M, Bjorntorp P, Sjostrom L, Smith U. Impact of obesity on metabolism in men and women. Importance of regional adipose tissue distribution. J Clin Invest. 1983;72:1150–1162.
    1. Poehlman ET, Toth MJ, Gardner AW. Changes in energy balance and body composition at menopause: a controlled longitudinal study. Ann Intern Med. 1995;123:673–675.
    1. Carr MC. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab. 2003;88:2404–2411. doi: 10.1210/jc.2003-030242.
    1. Kopp HP, Festa A, Krugluger W, Schernthaner G. Low levels of sex-hormone-binding globulin predict insulin requirement in patients with gestational diabetes mellitus. Exp Clin Endocrinol Diabetes. 2001;109:365–369. doi: 10.1055/s-2001-17408.
    1. Kirschner MA, Samojlik E. Sex hormone metabolism in upper and lower body obesity. Int J Obes. 1991;15 Suppl 2:101–108.
    1. Deslypere JP, Verdonck L, Vermeulen A. Fat tissue: a steroid reservoir and site of steroid metabolism. J Clin Endocrinol Metab. 1985;61:564–570.
    1. Corbould AM, Bawden MJ, Lavranos TC, Rodgers RJ, Judd SJ. The effect of obesity on the ratio of type 3 17beta-hydroxysteroid dehydrogenase mRNA to cytochrome P450 aromatase mRNA in subcutaneous abdominal and intra-abdominal adipose tissue of women. Int J Obes Relat Metab Disord. 2002;26:165–175. doi: 10.1038/sj.ijo.0801886.
    1. Corbould AM, Judd SJ, Rodgers RJ. Expression of types 1, 2, and 3 17 beta-hydroxysteroid dehydrogenase in subcutaneous abdominal and intra-abdominal adipose tissue of women. J Clin Endocrinol Metab. 1998;83:187–194. doi: 10.1210/jc.83.1.187.
    1. Tchernof A, Desmeules A, Richard C, Laberge P, Daris M, Mailloux J, Rheaume C, Dupont P. Ovarian hormone status and abdominal visceral adipose tissue metabolism. J Clin Endocrinol Metab. 2004;89:3425–3430. doi: 10.1210/jc.2003-031561.
    1. Enzi G, Gasparo M, Biondetti PR, Fiore D, Semisa M, Zurlo F. Subcutaneous and visceral fat distribution according to sex, age, and overweight, evaluated by computed tomography. Am J Clin Nutr. 1986;44:739–746.
    1. Lemieux S, Prud'homme D, Bouchard C, Tremblay A, Despres JP. Sex differences in the relation of visceral adipose tissue accumulation to total body fatness. Am J Clin Nutr. 1993;58:463–467.
    1. Park HS, Lee KU. Postmenopausal women lose less visceral adipose tissue during a weight reduction program. Menopause. 2003;10:222–227. doi: 10.1097/00042192-200310030-00009.
    1. Pottratz ST, Bellido T, Mocharla H, Crabb D, Manolagas SC. 17 beta-Estradiol inhibits expression of human interleukin-6 promoter-reporter constructs by a receptor-dependent mechanism. J Clin Invest. 1994;93:944–950.
    1. Straub RH, Hense HW, Andus T, Scholmerich J, Riegger GA, Schunkert H. Hormone replacement therapy and interrelation between serum interleukin-6 and body mass index in postmenopausal women: a population-based study. J Clin Endocrinol Metab. 2000;85:1340–1344. doi: 10.1210/jc.85.3.1340.
    1. Fernandez-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev. 2003;24:278–301. doi: 10.1210/er.2002-0010.
    1. Newton KM, LaCroix AZ, Heckbert SR, Abraham L, McCulloch D, Barlow W. Estrogen therapy and risk of cardiovascular events among women with type 2 diabetes. Diabetes Care. 2003;26:2810–2816.
    1. Dallongeville J, Marecaux N, Isorez D, Zylbergberg G, Fruchart JC, Amouyel P. Multiple coronary heart disease risk factors are associated with menopause and influenced by substitutive hormonal therapy in a cohort of French women. Atherosclerosis. 1995;118:123–133. doi: 10.1016/0021-9150(95)05599-R.
    1. Harvie M, Hooper L, Howell AH. Central obesity and breast cancer risk: a systematic review. Obes Rev. 2003;4:157–173. doi: 10.1046/j.1467-789X.2003.00108.x.
    1. Kazer RR. Insulin resistance, insulin-like growth factor I and breast cancer: a hypothesis. Int J Cancer. 1995;62:403–406.
    1. Ten great public health achievements -- United States, 1900-1999. MMWR. 1999;48:241–243.
    1. Roduit R, Nolan C, Alarcon C, Moore P, Barbeau A, Delghingaro-Augusto V, Przybykowski E, Morin J, Masse F, Massie B, Ruderman N, Rhodes C, Poitout V, Prentki M. A role for the malonyl-CoA/long-chain acyl-CoA pathway of lipid signaling in the regulation of insulin secretion in response to both fuel and nonfuel stimuli. Diabetes. 2004;53:1007–1019.
    1. Listenberger LL, Han X, Lewis SE, Cases S, Farese R. V., Jr., Ory DS, Schaffer JE. Triglyceride accumulation protects against fatty acid-induced lipotoxicity. Proc Natl Acad Sci U S A. 2003;100:3077–3082. doi: 10.1073/pnas.0630588100.
    1. Pettus BJ, Chalfant CE, Hannun YA. Ceramide in apoptosis: an overview and current perspectives. Biochim Biophys Acta. 2002;1585:114–125.
    1. Phinney SD, Bistrian BR, Wolfe RR, Blackburn GL. The human metabolic response to chronic ketosis without caloric restriction: physical and biochemical adaptation. Metabolism. 1983;32:757–768. doi: 10.1016/0026-0495(83)90105-1.
    1. Baratta M. Leptin--from a signal of adiposity to a hormonal mediator in peripheral tissues. Med Sci Monit. 2002;8:RA282–92.
    1. Kolaczynski JW, Ohannesian JP, Considine RV, Marco CC, Caro JF. Response of leptin to short-term and prolonged overfeeding in humans. J Clin Endocrinol Metab. 1996;81:4162–4165. doi: 10.1210/jc.81.11.4162.
    1. Evans K, Clark ML, Frayn KN. Carbohydrate and fat have different effects on plasma leptin concentrations and adipose tissue leptin production. Clin Sci (Lond) 2001;100:493–498.
    1. Yannakoulia M, Yiannakouris N, Bluher S, Matalas AL, Klimis-Zacas D, Mantzoros CS. Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans. J Clin Endocrinol Metab. 2003;88:1730–1736. doi: 10.1210/jc.2002-021604.
    1. Minokoshi Y, Kim YB, Peroni OD, Fryer LG, Muller C, Carling D, Kahn BB. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature. 2002;415:339–343. doi: 10.1038/415339a.
    1. Minokoshi Y, Kahn BB. Role of AMP-activated protein kinase in leptin-induced fatty acid oxidation in muscle. Biochem Soc Trans. 2003;31:196–201.
    1. Zhou YT, Wang ZW, Higa M, Newgard CB, Unger RH. Reversing adipocyte differentiation: implications for treatment of obesity. Proc Natl Acad Sci U S A. 1999;96:2391–2395. doi: 10.1073/pnas.96.5.2391.
    1. O'Rourke L, Gronning LM, Yeaman SJ, Shepherd PR. Glucose-dependent regulation of cholesterol ester metabolism in macrophages by insulin and leptin. J Biol Chem. 2002;277:42557–42562. doi: 10.1074/jbc.M202151200.
    1. Landsberg L. Insulin-mediated sympathetic stimulation: role in the pathogenesis of obesity-related hypertension (or, how insulin affects blood pressure, and why) J Hypertens. 2001;19:523–528. doi: 10.1097/00004872-200103001-00001.
    1. Zimmet P, Boyko EJ, Collier GR, de Courten M. Etiology of the metabolic syndrome: potential role of insulin resistance, leptin resistance, and other players. Ann N Y Acad Sci. 1999;892:25–44.
    1. Unger RH, ORCI L. Diseases of liporegulation: new perspective on obesity and related disorders. FASEB J. 2001;15:312–321. doi: 10.1096/fj.00-0590.
    1. Zhang Y, Guo KY, Diaz PA, Heo M, Leibel RL. Determinants of leptin gene expression in fat depots of lean mice. Am J Physiol Regul Integr Comp Physiol. 2002;282:R226–34.
    1. Banks WA, Coon AB, Robinson SM, Moinuddin A, Shultz JM, Nakaoke R, Morley JE. Triglycerides induce leptin resistance at the blood-brain barrier. Diabetes. 2004;53:1253–1260.
    1. Petersen KF, Oral EA, Dufour S, Befroy D, Ariyan C, Yu C, Cline GW, DePaoli AM, Taylor SI, Gorden P, Shulman GI. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest. 2002;109:1345–1350. doi: 10.1172/JCI200215001.
    1. Hegele RA. Familial partial lipodystrophy: a monogenic form of the insulin resistance syndrome. Mol Genet Metab. 2000;71:539–544. doi: 10.1006/mgme.2000.3092.
    1. Garg A, Peshock RM, Fleckenstein JL. Adipose tissue distribution pattern in patients with familial partial lipodystrophy (Dunnigan variety) J Clin Endocrinol Metab. 1999;84:170–174. doi: 10.1210/jc.84.1.170.
    1. Oral EA, Simha V, Ruiz E, Andewelt A, Premkumar A, Snell P, Wagner AJ, DePaoli AM, Reitman ML, Taylor SI, Gorden P, Garg A. Leptin-replacement therapy for lipodystrophy. N Engl J Med. 2002;346:570–578. doi: 10.1056/NEJMoa012437.
    1. Gavrilova O, Marcus-Samuels B, Graham D, Kim JK, Shulman GI, Castle AL, Vinson C, Eckhaus M, Reitman ML. Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. J Clin Invest. 2000;105:271–278.
    1. Colombo C, Cutson JJ, Yamauchi T, Vinson C, Kadowaki T, Gavrilova O, Reitman ML. Transplantation of adipose tissue lacking leptin is unable to reverse the metabolic abnormalities associated with lipoatrophy. Diabetes. 2002;51:2727–2733.
    1. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001;7:941–946. doi: 10.1038/90984.
    1. Matsuzawa Y. Establishing the concept of visceral fat syndrome and clarifying its molecular mechanisms. JMAJ. 2002;45:103–110.
    1. Nicklas BJ, Goldberg AP, Bunyard LB, Poehlman ET. Visceral adiposity is associated with increased lipid oxidation in obese, postmenopausal women. Am J Clin Nutr. 1995;62:918–922.
    1. Williams MJ, Hunter GR, Kekes-Szabo T, Trueth MS, Snyder S, Berland L, Blaudeau T. Intra-abdominal adipose tissue cut-points related to elevated cardiovascular risk in women. Int J Obes Relat Metab Disord. 1996;20:613–617.
    1. Brochu M, Tchernof A, Turner AN, Ades PA, Poehlman ET. Is there a threshold of visceral fat loss that improves the metabolic profile in obese postmenopausal women? Metabolism. 2003;52:599–604. doi: 10.1053/meta.2003.50095.
    1. Despres JP, Lamarche B. Effects of diet and physical activity on adiposity and body fat distribution: implications for the prevention of cardiovascular disease. Nutr Res Rev. 1993;6:137–159.
    1. Hunter GR, Snyder SW, Kekes-Szabo T, Nicholson C, Berland L. Intra-abdominal adipose tissue variables associated with risk of possessing elevated blood lipids and blood pressure. Int J Obes. 1994;2:563–569.
    1. Tanaka K, Okura T, Shigematsu R, Nakata Y, Lee DJ, Wee SW, Yamabuki K. Target value of intraabdominal fat area for improving coronary heart disease risk factors. Obes Res. 2004;12:695–703.
    1. Lemieux S, Prud'homme D, Bouchard C, Tremblay A, Despres JP. A single threshold value of waist girth identifies normal-weight and overweight subjects with excess visceral adipose tissue. Am J Clin Nutr. 1996;64:685–693.
    1. Perusse L, Despres JP, Lemieux S, Rice T, Rao DC, Bouchard C. Familial aggregation of abdominal visceral fat level: results from the Quebec family study. Metabolism. 1996;45:378–382. doi: 10.1016/S0026-0495(96)90294-2.
    1. Nicklas BJ, Penninx BW, Ryan AS, Berman DM, Lynch NA, Dennis KE. Visceral adipose tissue cutoffs associated with metabolic risk factors for coronary heart disease in women. Diabetes Care. 2003;26:1413–1420.
    1. DeNino WF, Tchernof A, Dionne IJ, Toth MJ, Ades PA, Sites CK, Poehlman ET. Contribution of abdominal adiposity to age-related differences in insulin sensitivity and plasma lipids in healthy nonobese women. Diabetes Care. 2001;24:925–932.
    1. Saito Y, Kobayashi J, Seimiya K, Hikita M, Takahashi K, Murano S, Bujo H, Morisaki N. Contribution of visceral fat accumulation to postprandial hyperlipidemia in human obesity. Eighth International Congress on Obesity. Int J Obes. 1998;Suppl 3:S226.
    1. Boyko EJ, Fujimoto WY, Leonetti DL, Newell-Morris L. Visceral adiposity and risk of type 2 diabetes: a prospective study among Japanese Americans. Diabetes Care. 2000;23:465–471.
    1. Hayashi T, Boyko EJ, Leonetti DL, McNeely MJ, Newell-Morris L, Kahn SE, Fujimoto WY. Visceral adiposity is an independent predictor of incident hypertension in Japanese Americans. Ann Intern Med. 2004;140:992–1000.
    1. Ruderman NB, Schneider SH, Berchtold P. The "metabolically-obese," normal-weight individual. Am J Clin Nutr. 1981;34:1617–1621.
    1. Ruderman NB, Berchtold P, Schneider S. Obesity-associated disorders in normal-weight individuals: some speculations. Int J Obes. 1982;6 Suppl 1:151–157.
    1. Looker HC, Knowler WC, Hanson RL. Changes in BMI and weight before and after the development of type 2 diabetes. Diabetes Care. 2001;24:1917–1922.
    1. Dvorak RV, DeNino WF, Ades PA, Poehlman ET. Phenotypic characteristics associated with insulin resistance in metabolically obese but normal-weight young women. Diabetes. 1999;48:2210–2214.
    1. Karelis AD, St-Pierre DH, Conus F, Rabasa-Lhoret R, Poehlman ET. Metabolic and body composition factors in subgroups of obesity: what do we know? J Clin Endocrinol Metab. 2004;89:2569–2575. doi: 10.1210/jc.2004-0165.
    1. Phillips DI, Barker DJ, Hales CN, Hirst S, Osmond C. Thinness at birth and insulin resistance in adult life. Diabetologia. 1994;37:150–154. doi: 10.1007/s001250050086.
    1. Kuh D, Hardy R, Chaturvedi N, Wadsworth ME. Birth weight, childhood growth and abdominal obesity in adult life. Int J Obes Relat Metab Disord. 2002;26:40–47. doi: 10.1038/sj.ijo.0801861.
    1. Park YW, Allison DB, Heymsfield SB, Gallagher D. Larger amounts of visceral adipose tissue in Asian Americans. Obes Res. 2001;9:381–387.
    1. Takami K, Takeda N, Nakashima K, Takami R, Hayashi M, Ozeki S, Yamada A, Kokubo Y, Sato M, Kawachi S, Sasaki A, Yasuda K. Effects of dietary treatment alone or diet with voglibose or glyburide on abdominal adipose tissue and metabolic abnormalities in patients with newly diagnosed type 2 diabetes. Diabetes Care. 2002;25:658–662.
    1. Hodge AM, Dowse GK, Collins VR, Zimmet PZ. Mortality in Micronesian Nauruans and Melanesian and Indian Fijians is not associated with obesity. Am J Epidemiol. 1996;143:442–455.
    1. Ferrannini E, Natali A, Bell P, Cavallo-Perin P, Lalic N, Mingrone G. Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR) J Clin Invest. 1997;100:1166–1173.
    1. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G, Alberiche M, Bonadona RC, Muggeo M. Prevalence of insulin resistance in metabolic disorders: The Bruneck Study. Diabetes. 1998;47:1643–1649.
    1. Brochu M, Tchernof A, Dionne IJ, Sites CK, Eltabbakh GH, Sims EA, Poehlman ET. What are the physical characteristics associated with a normal metabolic profile despite a high level of obesity in postmenopausal women? J Clin Endocrinol Metab. 2001;86:1020–1025. doi: 10.1210/jc.86.3.1020.
    1. Weyer C, Wolford JK, Hanson RL, Foley JE, Tataranni PA, Bogardus C, Pratley RE. Subcutaneous abdominal adipocyte size, a predictor of type 2 diabetes, is linked to chromosome 1q21--q23 and is associated with a common polymorphism in LMNA in Pima Indians. Mol Genet Metab. 2001;72:231–238. doi: 10.1006/mgme.2001.3147.
    1. Salans LB, Cushman SW, Weismann RE. Studies of human adipose tissue. Adipose cell size and number in nonobese and obese patients. J Clin Invest. 1973;52:929–941.
    1. Travers SH, Jeffers BW, Eckel RH. Insulin resistance during puberty and future fat accumulation. J Clin Endocrinol Metab. 2002;87:3814–3818. doi: 10.1210/jc.87.8.3814.
    1. Caprio S, Hyman LD, Limb C, McCarthy S, Lange R, Sherwin RS, Shulman G, Tamborlane WV. Central adiposity and its metabolic correlates in obese adolescent girls. Am J Physiol. 1995;269:E118–26.
    1. l'Allemand D, Schmidt S, Rousson V, Brabant G, Gasser T, Gruters A. Associations between body mass, leptin, IGF-I and circulating adrenal androgens in children with obesity and premature adrenarche. Eur J Endocrinol. 2002;146:537–543.
    1. Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A, Langenbach J, Willenberg HS, Barthel A, Hauner H, McCann SM, Scherbaum WA, Bornstein SR. Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci U S A. 2003;100:14211–14216. doi: 10.1073/pnas.2336140100.
    1. Owens S, Gutin B, Allison J, Riggs S, Ferguson M, Litaker M, Thompson W. Effect of physical training on total and visceral fat in obese children. Med Sci Sports Exerc. 1999;31:143–148. doi: 10.1097/00005768-199901000-00022.
    1. Gutin B, Barbeau P, Owens S, Lemmon CR, Bauman M, Allison J, Kang HS, Litaker MS. Effects of exercise intensity on cardiovascular fitness, total body composition, and visceral adiposity of obese adolescents. Am J Clin Nutr. 2002;75:818–826.
    1. Irwin ML, Ainsworth BE. Physical activity interventions following cancer diagnosis: methodologic challenges to delivery and assessment. Cancer Invest. 2004;22:30–50. doi: 10.1081/CNV-120027579.
    1. Ross R, Janssen I, Dawson J, Kungl AM, Kuk JL, Wong SL, Nguyen-Duy TB, Lee S, Kilpatrick K, Hudson R. Exercise-induced reduction in obesity and insulin resistance in women: a randomized controlled trial. Obes Res. 2004;12:789–798.
    1. Irwin ML, Yasui Y, Ulrich CM, Bowen D, Rudolph RE, Schwartz RS, Yukawa M, Aiello E, Potter JD, McTiernan A. Effect of exercise on total and intra-abdominal body fat in postmenopausal women: a randomized controlled trial. Jama. 2003;289:323–330. doi: 10.1001/jama.289.3.323.
    1. Wong SL, Katzmarzyk P, Nichaman MZ, Church TS, Blair SN, Ross R. Cardiorespiratory fitness is associated with lower abdominal fat independent of body mass index. Med Sci Sports Exerc. 2004;36:286–291.
    1. Church TS, Cheng YJ, Earnest CP, Barlow CE, Gibbons LW, Priest EL, Blair SN. Exercise capacity and body composition as predictors of mortality among men with diabetes. Diabetes Care. 2004;27:83–88.
    1. Wei M, Gibbons LW, Kampert JB, Nichaman MZ, Blair SN. Low cardiorespiratory fitness and physical inactivity as predictors of mortality in men with type 2 diabetes [see comments] Ann Intern Med. 2000;132:605–611.
    1. Church TS, Barlow CE, Earnest CP, Kampert JB, Priest EL, Blair SN. Associations between cardiorespiratory fitness and C-reactive protein in men. Arterioscler Thromb Vasc Biol. 2002;22:1869–1876. doi: 10.1161/01.ATV.0000036611.77940.F8.
    1. Katzmarzyk PT, Church TS, Blair SN. Cardiorespiratory fitness attenuates the effects of the metabolic syndrome on all-cause and cardiovascular disease mortality in men. Arch Intern Med. 2004;164:1092–1097. doi: 10.1001/archinte.164.10.1092.
    1. McGavock JM, Mandic S, Vonder Muhll I, Lewanczuk RZ, Quinney HA, Taylor DA, Welsh RC, Haykowsky M. Low cardiorespiratory fitness is associated with elevated C-reactive protein levels in women with type 2 diabetes. Diabetes Care. 2004;27:320–325.
    1. Goodpaster BH, Wolfe RR, Kelley DE. Effects of obesity on substrate utilization during exercise. Obes Res. 2002;10:575–584.
    1. Ross R, Dagnone D, Jones PJ, Smith H, Paddags A, Hudson R, Janssen I. Reduction in obesity and related comorbid conditions after diet-induced weight loss or exercise-induced weight loss in men. A randomized, controlled trial. Ann Intern Med. 2000;133:92–103.
    1. Thompson PD, Crouse SF, Goodpaster B, Kelley D, Moyna N, Pescatello L. The acute versus the chronic response to exercise. Med Sci Sports Exerc. 2001;33:S438–45; discussion S452-3.
    1. Janssen I, Katzmarzyk PT, Ross R, Leon AS, Skinner JS, Rao DC, Wilmore JH, Rankinen T, Bouchard C. Fitness alters the associations of BMI and waist circumference with total and abdominal fat. Obes Res. 2004;12:525–537.
    1. Dattilo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr. 1992;56:320–328.
    1. Paffenbarger R. S., Jr., Hyde RT, Wing AL, Lee IM, Jung DL, Kampert JB. The association of changes in physical-activity level and other lifestyle characteristics with mortality among men. N Engl J Med. 1993;328:538–545. doi: 10.1056/NEJM199302253280804.
    1. Cuff DJ, Meneilly GS, Martin A, Ignaszewski A, Tildesley HD, Frohlich JJ. Effective exercise modality to reduce insulin resistance in women with type 2 diabetes. Diabetes Care. 2003;26:2977–2982.
    1. Holten MK, Zacho M, Gaster M, Juel C, Wojtaszewski JF, Dela F. Strength training increases insulin-mediated glucose uptake, GLUT4 content, and insulin signaling in skeletal muscle in patients with type 2 diabetes. Diabetes. 2004;53:294–305.
    1. Grady D. New York Times. New York; 2004. Fat: the secret life of a potent cell. July 6.
    1. Weber RV, Buckley MC, Fried SK, Kral JG. Subcutaneous lipectomy causes a metabolic syndrome in hamsters. Am J Physiol Regul Integr Comp Physiol. 2000;279:R936–43.
    1. Pelletier C, Despres JP, Tremblay A. Plasma organochlorine concentrations in endurance athletes and obese individuals. Med Sci Sports Exerc. 2002;34:1971–1975. doi: 10.1097/00005768-200212000-00017.
    1. Pelletier C, Doucet E, Imbeault P, Tremblay A. Associations between weight loss-induced changes in plasma organochlorine concentrations, serum T(3) concentration, and resting metabolic rate. Toxicol Sci. 2002;67:46–51.
    1. Imbeault P, Tremblay A, Simoneau JA, Joanisse DR. Weight loss-induced rise in plasma pollutant is associated with reduced skeletal muscle oxidative capacity. Am J Physiol Endocrinol Metab. 2002;282:E574–9.
    1. Baillie-Hamilton PF. Chemical toxins: a hypothesis to explain the global obesity epidemic. J Altern Complement Med. 2002;8:185–192. doi: 10.1089/107555302317371479.
    1. Frisancho AR. Reduced rate of fat oxidation: A metabolic pathway to obesity in the developing nations. Am J Human Biol. 2003;15:522–532. doi: 10.1002/ajhb.10191.
    1. Bisschop PH, Pereira Arias AM, Ackermans MT, Endert E, Pijl H, Kuipers F, Meijer AJ, Sauerwein HP, Romijn JA. The effects of carbohydrate variation in isocaloric diets on glycogenolysis and gluconeogenesis in healthy men. J Clin Endocrinol Metab. 2000;85:1963–1967. doi: 10.1210/jc.85.5.1963.
    1. Sharman MJ, Kraemer WJ, Love DM, Avery NG, Gomez AL, Scheett TP, Volek JS. A ketogenic diet favorably affects serum biomarkers for cardiovascular disease in normal-weight men. J Nutr. 2002;132:1879–1885.
    1. Ludwig DS. The glycemic index: physiological mechanisms relating to obesity, diabetes, and cardiovascular disease. Jama. 2002;287:2414–2423. doi: 10.1001/jama.287.18.2414.
    1. Ludwig DS. Glycemic load comes of age. J Nutr. 2003;133:2695–2696.
    1. Ebbeling CB, Ludwig DS. Treating obesity in youth: should dietary glycemic load be a consideration? Adv Pediatr. 2001;48:179–212.
    1. Silvestre R, Sharman MJ, Gomez AL, Judelson DA, Watson G, Ruffin K, Kraemer WJ, Volek JS. Kingsbrook conference on nutritional and metabolic aspects of low carbohydrate diets. Brooklyn, University of Connecticut (Storrs); 2004. A very low-carbohydrate diet results in greater reductions in body weight, whole body fat, and trunk fat than a low-fat diet in overweight subjects.
    1. Kabir M, Rizkalla SW, Quignard-Boulange A, Guerre-Millo M, Boillot J, Ardouin B, Luo J, Slama G. A high glycemic index starch diet affects lipid storage-related enzymes in normal and to a lesser extent in diabetic rats. J Nutr. 1998;128:1878–1883.
    1. Lerer-Metzger M, Rizkalla SW, Luo J, Champ M, Kabir M, Bruzzo F, Bornet F, Slama G. Effects of long-term low-glycaemic index starchy food on plasma glucose and lipid concentrations and adipose tissue cellularity in normal and diabetic rats. Br J Nutr. 1996;75:723–732.
    1. Kim JY, Nolte LA, Hansen PA, Han DH, Kawanaka K, Holloszy JO. Insulin resistance of muscle glucose transport in male and female rats fed a high-sucrose diet. Am J Physiol. 1999;276:R665–72.
    1. Keno Y, Matsuzawa Y, Tokunaga K, Fujioka S, Kawamoto T, Kobatake T, Tarui S. High sucrose diet increases visceral fat accumulation in VMH-lesioned obese rats. Int J Obes. 1991;15:205–211.
    1. Liu S, Manson JE, Buring JE, Stampfer MJ, Willett WC, Ridker PM. Relation between a diet with a high glycemic load and plasma concentrations of high-sensitivity C-reactive protein in middle-aged women. Am J Clin Nutr. 2002;75:492–498.
    1. Erickson KL. Is there a relation between dietary linoleic acid and cancer of the breast, colon, or prostate? Am J Nutr. 1998;68:5–7.
    1. McKeown NM, Meigs JB, Liu S, Saltzman E, Wilson PW, Jacques PF. Carbohydrate nutrition, insulin resistance, and the prevalence of the metabolic syndrome in the Framingham Offspring Cohort. Diabetes Care. 2004;27:538–546.
    1. O'Brien KD, Brehm BJ, Seeley RJ. Greater reduction in inflammatory markers with a low carbohydrate diet than with a low fat diet. American Heart Association Scientific Sessions. 2002;Abst # 117597 November 19.
    1. Mohanty Priya, Ghanim Husam, Hamouda Wael, Aljada Ahmad, Garg Rajesh, Dandona Paresh. Both lipid and protein intakes stimulate increased generation of reactive oxygen species by polymorphonuclear leukocytes and mononuclear cells. Am J Clin Nutr. 2002;75:767–772.
    1. Mohanty P, Hamouda W, Garg R, Aljada A, Ghanim H, Dandona P. Glucose challenge stimulates reactive oxygen species (ROS) generation by leucocytes. J Clin Endocrinol Metab. 2000;85:2970–2973. doi: 10.1210/jc.85.8.2970.
    1. Clark JM. Annual Meeting of the American Assocation for the Study of Liver Disease. Boston, MA, Abst 734; 2003. Dietary composition and fatty liver disease.
    1. Larson DE, Hunter GR, Williams MJ, Kekes-Szabo T, Nyikos I, Goran MI. Dietary fat in relation to body fat and intraabdominal adipose tissue: a cross-sectional analysis. Am J Clin Nutr. 1996;64:677–684.
    1. Alessi MC, Morange P, Juhan-Vague I. Fat cell function and fibrinolysis. Horm Metab Res. 2000;32:504–508.
    1. Jarvi AE, Karlstrom BE, Granfeldt YE, Bjorck IE, Asp NG, Vessby BO. Improved glycemic control and lipid profile and normalized fibrinolytic activity on a low-glycemic index diet in type 2 diabetic patients. Diabetes Care. 1999;22:10–18.
    1. Gabriely I, Yang XM, Cases JA, Ma XH, Rossetti L, Barzilai N. Hyperglycemia induces PAI-1 gene expression in adipose tissue by activation of the hexosamine biosynthetic pathway. Atherosclerosis. 2002;160:115–122. doi: 10.1016/S0021-9150(01)00574-3.
    1. Rosmond R, Bjorntorp P. Quality of life, overweight, and body fat distribution in middle-aged men.[In Process Citation] Behav Med. 2000;26:90–94.
    1. Rosmond R, Bjorntorp P. Occupational status, cortisol secretory pattern, and visceral obesity in middle-aged men. Obes Res. 2000;8:445–450.
    1. Rosmond R, Dallman MF, Bjorntorp P. Stress-related cortisol secretion in men: relationships with abdominal obesity and endocrine, metabolic and hemodynamic abnormalities [see comments] J Clin Endocrinol Metab. 1998;83:1853–1859. doi: 10.1210/jc.83.6.1853.
    1. Mooy JM, de Vries H, Grootenhuis PA, Bouter LM, Heine RJ. Major stressful life events in relation to prevalence of undetected type 2 diabetes: the Hoorn Study. Diabetes Care. 2000;23:197–201.
    1. Bjorntorp P, Holm G, Rosmond R, Folkow B. Hypertension and the metabolic syndrome: closely related central origin? Blood Press. 2000;9:71–82. doi: 10.1080/08037050050151762.
    1. Rosmond R, Bjorntorp P. The role of antidepressants in the treatment of abdominal obesity. Med Hypotheses. 2000;54:990–994. doi: 10.1054/mehy.1999.1005.
    1. Bjorntorp P, Rosmond R. Obesity and cortisol [In Process Citation] Nutrition. 2000;16:924–936. doi: 10.1016/S0899-9007(00)00422-6.
    1. Esposito-Del Puente A, Lillioja S, Bogardus C, McCubbin JA, Feinglos MN, Kuhn CM, Surwit RS. Glycemic response to stress is altered in euglycemic Pima Indians. Int J Obes Relat Metab Disord. 1994;18:766–770.
    1. Ghiadoni L, Donald AE, Cropley M, Mullen MJ, Oakley G, Taylor M, O'Connor G, Betteridge J, Klein N, Steptoe A, Deanfield JE. Mental stress induces transient endothelial dysfunction in humans [In Process Citation] Circulation. 2000;102:2473–2478.
    1. Sarabi M, Lind L. Mental stress opposes endothelium-dependent vasodilation in young healthy individuals. Vasc Med. 2001;6:3–7. doi: 10.1191/135886301673856082.
    1. Reichenberg A, Yirmiya R, Schuld A, Kraus T, Haack M, Morag A, Pollmacher T. Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry. 2001;58:445–452. doi: 10.1001/archpsyc.58.5.445.
    1. Stoney CM, West SG, Hughes JW, Lentino LM, Finney ML, Falko J, Bausserman L. Acute psychological stress reduces plasma triglyceride clearance. Psychophysiology. 2002;39:80–85. doi: 10.1017/S0048577202010284.
    1. Black PH. Stress and the inflammatory response: a review of neurogenic inflammation. Brain Behav Immun. 2002;16:622–653. doi: 10.1016/S0889-1591(02)00021-1.
    1. Black PH, Garbutt LD. Stress, inflammation and cardiovascular disease. J Psychosom Res. 2002;52:1–23. doi: 10.1016/S0022-3999(01)00302-6.
    1. Black PH. The inflammatory response is an integral part of the stress response: Implications for atherosclerosis, insulin resistance, type II diabetes and metabolic syndrome X. Brain Behav Immun. 2003;17:350–364. doi: 10.1016/S0889-1591(03)00048-5.
    1. Pickup JC, Mattock MB. Activation of the innate immune system as a predictor of cardiovascular mortality in Type 2 diabetes mellitus. Diabet Med. 2003;20:723–726. doi: 10.1046/j.1464-5491.2003.00990.x.
    1. Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care. 2004;27:813–823.
    1. Young JB, Weiss J, Boufath N. Effects of dietary monosaccharides on sympathetic nervous system activity in adipose tissues of male rats. Diabetes. 2004;53:1271–1278.
    1. Karpe F, Fielding BA, Ilic V, Macdonald IA, Summers LK, Frayn KN. Impaired postprandial adipose tissue blood flow response is related to aspects of insulin sensitivity. Diabetes. 2002;51:2467–2473.
    1. Bjorntorp P. Do stress reactions cause abdominal obesity and comorbidities? Obes Rev. 2001;2:73–86. doi: 10.1046/j.1467-789x.2001.00027.x.
    1. Dallman MF, Pecoraro N, Akana SF, La Fleur SE, Gomez F, Houshyar H, Bell ME, Bhatnagar S, Laugero KD, Manalo S. Chronic stress and obesity: a new view of "comfort food". Proc Natl Acad Sci U S A. 2003;100:11696–11701. doi: 10.1073/pnas.1934666100.
    1. Franco-Colin M, Tellez-Lopez AM, Quevedo-Corona L, Racotta R. Effects of long-term high-sucrose and dexamethasone on fat depots, liver fat, and lipid fuel fluxes through the retroperitoneal adipose tissue and splanchnic area in rats. Metabolism. 2000;49:1289–1294. doi: 10.1053/meta.2000.9522.
    1. Surwit RS, van Tilburg MA, Zucker N, McCaskill CC, Parekh P, Feinglos MN, Edwards CL, Williams P, Lane JD. Stress management improves long-term glycemic control in type 2 diabetes. Diabetes Care. 2002;25:30–34.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다